The PK/PD of Deoxycholic Acid Amphotericin B in Invasive Fungal Infection Patients With Sepsis/Septic Shock
Launched by SOUTHEAST UNIVERSITY, CHINA · Nov 29, 2022
Trial Information
Current as of January 16, 2025
Completed
Keywords
ClinConnect Summary
This was a single-center study.Patients who were diagnosed with in invasive fungal infection receieved deoxycholic acid amphotericin B during the study period.The information was recored including the general condition, infection index, PK/PD index and drug-related side effects.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patients age more than 18 years old; Meet the criteria of Sepsis 3.0; Admitted to ICU; Patients were suspected or diagnosis of IFI,doctors determined the use of deoxycholic acid amphotericin B.
- Exclusion Criteria:
- • Serum creatinine≥221umol/L; Deoxycholic acid amphotericin B or amphotericin B liposome were used for the past 7 days; Patients being treated with rifampicin; Unable to tolerate treatment of deoxycholic acid amphotericin B; BMI\<18.5 or \>30; Tumors; Pregnancy; Estimated time of survival\<24h; Patients who participated in other studies within 30 days.
Trial Officials
Huang Yingzi, PHD
Principal Investigator
Zhongda Hospital
About Southeast University, China
Southeast University, located in Nanjing, China, is a prestigious institution renowned for its commitment to advancing medical research and clinical innovation. With a strong emphasis on interdisciplinary collaboration, the university leverages its robust academic resources and state-of-the-art facilities to conduct clinical trials that aim to address pressing healthcare challenges. Southeast University actively engages in partnerships with healthcare organizations and industry leaders to facilitate cutting-edge research, enhance patient outcomes, and contribute to the global medical community. Through its dedicated focus on ethical standards and scientific rigor, Southeast University is poised to make significant contributions to the field of clinical research.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Nanjing, Jiangsu, China
Nanjing, Jiangsu, China
People applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Discussion 0
Similar Trials